ESC Congress 2025 - Paclitaxel-coated devices in critical limb threatening ischemia were not effective in preventing amputation, nor improving quality-of-life in intermittent claudication.

Dr Mårten Falkenberg (Sahlgrenska University Hospital, Gothenburg, SE) and Prof Joakim Nordanstig (Sahlgrenska University Hospital, Gothenburg, SE) join us to discuss findings from the SWEDEPAD 1 and 2 parallel studies. The multicenter, prospective, randomised trial investigated the impact of drug-coated devices in patients with PAD based on the Swedish Vascular Registry Platform. Patients with critical limb ischemia were enrolled to SWEDEPAD 1 and patients with intermittent claudication were enrolled to SWEDEPAD 2.

Findings showed that in both CLTI and intermittent claudication, paclitaxel coated devices were not associated with reduced risk of amputation or improved quality of life compared to uncoated devices.

Interview Questions:

1. What is the reasoning behind SWEDEPAD 1 and 2?
2. What was the study design and patient population?
3. What were the key findings?
4. What are the take-home messages for practice?
5. What further research is needed in this area?

Recorded on-site at ESC Congress 2025, Madrid.

Editors: Jordan Rance, Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Vascular.